People: Rockwell Medical Inc (RMTI.OQ)
RMTI.OQ on NASDAQ Stock Exchange Global Market
4.98USD
1 Aug 2013
4.98USD
1 Aug 2013
Price Change (% chg)
$-0.07 (-1.39%)
$-0.07 (-1.39%)
Prev Close
$5.05
$5.05
Open
$5.08
$5.08
Day's High
$5.08
$5.08
Day's Low
$4.83
$4.83
Volume
119,940
119,940
Avg. Vol
214,509
214,509
52-wk High
$9.50
$9.50
52-wk Low
$3.16
$3.16
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Robert Chioini |
47 | 2000 | Chairman of the Board, President, Chief Executive Officer |
Thomas Klema |
58 | 1999 | Chief Financial Officer, Vice President, Treasurer, Secretary |
Ajay Gupta |
54 | 2009 | Chief Scientific Officer |
Raymond Pratt |
2012 | Chief Medical Officer | |
Patrick Bagley |
47 | 2005 | Independent Director |
Ronald Boyd |
49 | 2000 | Independent Director |
Kenneth Holt |
59 | 2000 | Independent Director |
Biographies
| Name | Description |
|---|---|
Robert Chioini |
Mr. Robert L. Chioini is the Chairman of the Board, President, Chief Executive Officer of Rockwell Medical Technologies Inc. He is a founder of the Company, has served as Chairman of the Board since March 2000, has served as President and Chief Executive Officer since February 1997, has been one of directors since formation in October 1996 and served as President of the Company’s predecessor which he founded in January 1995. Including his time with the Company, Mr. Chioini has nearly 20 years of operational and sales experience in the dialysis industry. |
Thomas Klema |
Mr. Thomas E. Klema, CPA, MBA, is Chief Financial Officer, Vice President, Treasurer, Secretary of Rockwell Medical Technologies Inc., since January 1999. Prior to joining the Company, Mr. Klema was employed as Vice President of Finance and Administration at a specialty products division of Whistler Corporation from 1997 to 1998 and, from 1980 to 1996, held several management positions in the areas of finance, accounting, human resources, business planning, customer service and operations, including from 1993 to 1996 as a vice president, at Diversey Corporation, a subsidiary of the Molson Cos., until it was acquired by Unilever. Prior to 1980, Mr. Klema was employed as a certified public accountant. Mr. Klema holds both an MBA in finance and a BA in accounting from Michigan State University. |
Ajay Gupta |
Dr. Ajay Gupta, M.D., is Chief Scientific Officer of Rockwell Medical Technologies Inc since June 2009. Prior to joining the Company, Dr. Gupta spent the prior seven years as an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine, Los Angeles, CA, where he had an active nephrology practice. Prior to that, Dr. Gupta served on the faculties of Henry Ford Hospital, Detroit, MI, University of Alabama, Birmingham, State University of New York, Syracuse and Washington University, St. Louis. Dr. Gupta also completed a clinical fellowship in Nephrology from Wayne State University, Detroit, Michigan and a research fellowship in Nephrology from Washington University, St. Louis, Missouri. Dr. Gupta, who is the Founder and Chairman of the Indian Society for Bone and Mineral Research, earned his MBBS degree and completed his residency in Internal Medicine from All India Institute of Medical Sciences, New Delhi. Dr. Gupta is the inventor of dialysate iron therapy using Soluble Ferric Pyrophosphate (SFP) and is also the inventor of intravenous iron therapy using slow continuous infusion of SFP, including as an adjunct to parenteral nutritional admixtures. He has filed a number of patents in the areas of drugs, medical devices and diagnostic tests. |
Raymond Pratt |
Dr. Raymond Pratt has been appointed as Chief Medical Officer of Rockwell Medical Technologies Inc., effective April 19, 2012. Prior to joining Rockwell Medical, Dr. Pratt worked at Shire PLLC from 2003 to 2010 as Vice President R&D and as the scientific leader in its Emerging Business Unit and Renal Business Unit. Previous roles at Shire included Vice President Global Clinical Medicine and Global Clinical Affairs and head of US Clinical Development. Dr. Pratt was instrumental in the FDA approval of Fosrenol ESRD indication and CKD non-dialysis indication in the European Union and United States. He was responsible for 3 new drug applications as well as multiple EU applications. He has managed 10 different drugs through all stages of global development for renal and other indications and has experience appearing before the FDA. Dr. Pratt served in a consulting role at Quintiles, a global biopharmaceutical services company, as a vice president of strategic drug development innovation since August 2011 and as an industry consultant during 2011 after leaving Shire. Prior to working at Shire, he was Senior Director, Clinical Research and Development at Eisai Medical Research from 1994 to 2003, where he was head of CNS and Internal Medicine clinical development. Dr. Pratt received his M.D. from the University of Illinois College of Medicine. He served six years in the U.S. Army Medical Corps including a period as Director, Dialysis Services at the Walter Reed Army Medical Center. He has served as an Assistant Professor at Cornell Medical College from 1993 to 1994 and at Johns Hopkins University School of Medicine from 1990 to 1993. |
Patrick Bagley |
Mr. Patrick J. Bagley is Independent Director of Rockwell Medical Technologies Inc since July 2005. Mr. Bagley is Senior Partner of the law firm Bagley and Langan, P.L.L.C. and has been a practicing attorney since 1995, with a focus on general legal matters and litigation. Since 1987, Mr. Bagley has also been a licensed insurance agent licensed and certified in property and casualty insurance as well as life, accident and health insurance. Mr. Bagley has started and managed numerous businesses, including three different national franchises of retail service businesses. In addition, since 1988, Mr. Bagley has been a licensed real estate agent, real estate developer and real estate investor. |
Ronald Boyd |
Mr. Ronald D. Boyd is Independent Director of Rockwell Medical Technologies Inc since March 2000. Mr. Boyd has over 26 years of experience in the dialysis industry, including the ownership and operation of dialysis clinics as well as experience in dialysis product design, product development, regulatory approval and marketing. He has also been a private investor for many years. He currently is an owner and managing partner of Southeast Acute Services, LLC and Southern Renal Administrations, LLC, which is primarily in the business of acute dialysis services, since 2001. He was a founder and Managing Partner of East Georgia Regional Dialysis Center, an outpatient, freestanding dialysis center located in southern Georgia from 2001 until 2005. He was a founder of Diatek, Inc. in 2001 where he developed, designed and holds the patent to the Cannon Cath., the first “retrograde” dual lumen dialysis catheter in the market. The company has since been sold. He was a founder and co-owner of Classic Medical, Inc., a dialysis and medical products company, and served as the Executive Vice President of Classic Medical, Inc. from its inception in November 1993 until April 2007 when he sold his interest in that company. From May 1993 to November 1993, Mr. Boyd served as a consultant for Dial Medical of Florida, Inc., a manufacturer and distributor of dialysis products. From 1990 to 1993, Mr. Boyd served as a Regional Sales Manager for Future Tech, Inc., a dialysis products distributor. |
Kenneth Holt |
Mr. Kenneth L. Holt is Independent Director of Rockwell Medical Technologies Inc since March 2000. Mr. Holt has over 25 years of experience in the dialysis industry, including the management and operation of dialysis clinics, and has also been a private investor for many years. He is currently an owner and a managing partner of two firms that provide contractual dialysis services, Southeast Acute Services, LLC and Southern Renal Administrators, since 2001. He was a founder and co-owner of Charleston Renal Care, LLC, a kidney disease management company specializing in the treatment of end-stage renal disease, until its sale in 2005. He was a founder and co-owner of Savannah Dialysis Specialists, LLC, a disease management company specializing in the treatment of end-stage renal disease, and served as the Managing Partner from October 1999 until its sale in 2004. From 1996 to October 1999, Mr. Holt served as Vice President for Gambro Healthcare, Inc., in its Carolinas Region, and held the same position at Vivra Renal Care, Inc., its predecessor company, which was acquired in 1997 by Gambro Healthcare, Inc. From 1986 to 1996, Mr. Holt was also the co-owner and Managing Partner of five other dialysis clinics that he founded. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Robert Chioini |
1,912,780 |
Thomas Klema |
880,590 |
Ajay Gupta |
1,200,260 |
Raymond Pratt |
-- |
Patrick Bagley |
-- |
Ronald Boyd |
-- |
Kenneth Holt |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Robert Chioini |
2,566,250 | 4,783,105 |
Thomas Klema |
1,173,750 | 2,473,705 |
Ajay Gupta |
0 | 0 |
Raymond Pratt |
0 | 0 |
Patrick Bagley |
0 | 0 |
Ronald Boyd |
0 | 0 |
Kenneth Holt |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CHIOINI ROBERT L |
58,000 | $4.12 |
KLEMA THOMAS E |
150,000 | $1.81 |
CHIOINI ROBERT L |
300,000 | $1.81 |
KLEMA THOMAS E |
65,898 | $4.12 |
GUPTA AJAY |
75,000 | $0.00 |
CHIOINI ROBERT L |
100,000 | $0.00 |
KLEMA THOMAS E |
60,000 | $0.00 |
PRATT RAYMOND DENNIS |
75,000 | $0.00 |
HOLT KENNETH L |
7,405 | $5.47 |
HOLT KENNETH L |
25,000 | $3.06 |
HOLT KENNETH L |
13,986 | $5.47 |
HOLT KENNETH L |
10,000 | $4.05 |
KLEMA THOMAS E |
68,000 | $0.55 |
KLEMA THOMAS E |
7,124 | $5.25 |
HOLT KENNETH L |
350 | $6.00 |
HOLT KENNETH L |
2,400 | $6.27 |
HOLT KENNETH L |
650 | $6.20 |
HOLT KENNETH L |
600 | $6.40 |
HOLT KENNETH L |
299 | $6.25 |
HAGELSTEIN DAVID A |
3,500 | $8.10 |
HAGELSTEIN DAVID A |
3,500 | $8.09 |
HAGELSTEIN DAVID A |
200 | $8.52 |
HAGELSTEIN DAVID A |
100 | $8.54 |
HAGELSTEIN DAVID A |
1,100 | $8.51 |
HAGELSTEIN DAVID A |
3,600 | $8.55 |

